Novartis to develop Homology Medicine’s AAV mediated gene editing technology, perhaps superior to CRISPR

Novartis has penned a new deal with Homology Medicines as it looks to boost its already impressive R&D work in cell and gene therapy.

https://www.fiercebiotech.com/biotech/novartis-already-up-crispr-car-t-looks-to-new-gene-editing-r-d

About Robert Zinn

Robert Zinn, M.D., Ph.D. is a medical doctor, physician, and web entrepreneur, who, for over 15 years was employed by academic and research institutions and focused his clinical practices on very specialized patient populations, such as those with rare genetic diseases or rare cancers. He shares his knowledge through his website, NutritionTheory.org

View all posts by Robert Zinn →